Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 15 February 2016, 15:10 HKT/SGT
Share:
    

Source: Eisai
Eisai and Sysmex Enter Comprehensive Agreement to Create Next-Generation Diagnostic Reagents in the Field of Dementia

TOKYO, Feb 15, 2016 - (JCN Newswire) - Eisai Co., Ltd. and Sysmex Corporation jointly announced that the two companies have entered into a comprehensive non-exclusive collaboration agreement aimed at the creation of new diagnostics in the field of dementia.

While diagnosis of Alzheimer's disease is sometimes made by using tests such as brain imaging examinations and cerebrospinal fluid examinations, various issues such as the insufficient number of facilities for examinations, the high cost, and the invasiveness of the testing remain to be addressed. As such, there is a need for the development of technologies that will enable diagnoses to be made in a manner that is easy, affordable and less invasive.

Sysmex possesses diverse expertise and know-how in the field of clinical diagnostics as well as effective technologies for highly sensitive detection of genetic, protein and cellular biomarkers in blood samples. Meanwhile, Eisai has a wealth of experience and knowledge cultivated though more than 30 years of drug discovery activities in the field of dementia as well as providing product-related information for the Alzheimer's disease / dementia with Lewy bodies treatment* Aricept(R).

Leveraging each other's technologies and knowledge, the two companies aim to discover next-generation diagnostics that will enable early diagnosis, selection of treatment options and the regular monitoring of the effects of treatment for dementia. In collaboration with Eisai, Sysmex will lead the development of diagnostics, and will exclusively market these diagnostics worldwide after receiving regulatory approval. Eisai will receive payments for meeting development milestones, launching products, as well as royalties on sales, and Eisai will utilize these next-generation diagnostics for drug discovery and development in the field of dementia.

Through this collaboration, Eisai and Sysmex aim to create new value in prevention, diagnosis and treatment of dementia, and to further contribute to addressing the diverse needs of, and increasing the benefits provided to, patients and their families.

* Indication of Aricept for the treatment of dementia with Lewy bodies is approved only in Japan.

About Sysmex

Sysmex provides customers in over 190 countries around the world with products and solutions for the testing of blood, urine and cell samples. As an integrated company which develops and manufactures the instruments, reagents and software that are needed for in vitro diagnostics, along with the necessary sales and support networks, Sysmex promotes research and technological development to create high value testing and diagnostic technologies in various clinical fields including oncology and chronic disease. For more information about Sysmex, please visit: http://www.sysmex.co.jp/en


Contact:
Public Relations Department
Eisai Co., Ltd.
TEL: +81-3-3817-5120

IR & Corporate Communication Department
Sysmex Corporation
TEL: +81-7-8265-0508


Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
July 31, 2025 08:30 HKT/SGT
Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI(R) (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
July 31, 2025 08:20 HKT/SGT
New Data Presented at AAIC Demonstrates Investigational LEQEMBI(R) (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease
July 31, 2025 08:10 HKT/SGT
Two-Year Real-World Study of LEQEMBI(R) in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025
July 29, 2025 08:01 HKT/SGT
LENVIMA(R) (lenvatinib) in Combination with Pembrolizumab and Transarterial Chemoembolization (TACE) Approved in China for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma
July 25, 2025 12:31 HKT/SGT
Eisai Listed for 24th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment
July 23, 2025 09:07 HKT/SGT
Launch of Beova(R) Tablets in Thailand for Overactive Bladder
July 22, 2025 10:56 HKT/SGT
Eisai To Present Four-Year Efficacy And Safety Data On Continuous Treatment With Lecanemab At The Alzheimer's Association International Conference 2025
July 16, 2025 13:50 HKT/SGT
Eisai Awarded "The 9th Bioindustry Award" for Drug Discovery Research for Anti- Amyloid B Monoclonal Antibody Lecanemab
July 14, 2025 09:20 HKT/SGT
"URECE" (Dotinurad) Launched in China as a treatment for Gout
July 8, 2025 08:31 HKT/SGT
Eisai Selected as Supplier Engagement Leader, CDP's Highest Rating in the Supplier Engagement Assessment
More news >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: